Project Details
Description
Chronic hepatitis B (CHB) caused by the persistent infection of Hepatitis B virus (HBV) is a major
health burden globally. In Australia, 11% of Australians living with CHB are Aboriginal and Torres
Strait Islander people. It is widely accepted that as a non-cytopathic virus, the liver pathology caused
by CHB is largely due to the inflammatory response that lacks specificity. Recent evidence suggested
that humoral immunity against HBV antigens, which resulted in immune complex formation and
subsequent complement activation, contributed to virus-induced fulminant hepatitis. Our previous
study indicated that naked capsid could be released into circulation and formed capsid-antibodycomplexes (CACs) in sera of CHB patients (J.Virol 2018:e00798-18). Recently, we have developed
and validated a novel microplate-based C1q (an essential component of complement system)
capture assay which enables relative quantification of Capsid-specific immune complex in patient
serum. Here, we plan to further evaluate this assay using clinical samples from CHB patients in
Australia, and systematically analyse its statistical relationship with the major clinical parameters
related to stage of disease. This new assay has the potential to reveal the underlying inflammation
that might be missed by conventional biochemical test. It may also be useful for monitoring the
efficacy of current antiviral therapy.
health burden globally. In Australia, 11% of Australians living with CHB are Aboriginal and Torres
Strait Islander people. It is widely accepted that as a non-cytopathic virus, the liver pathology caused
by CHB is largely due to the inflammatory response that lacks specificity. Recent evidence suggested
that humoral immunity against HBV antigens, which resulted in immune complex formation and
subsequent complement activation, contributed to virus-induced fulminant hepatitis. Our previous
study indicated that naked capsid could be released into circulation and formed capsid-antibodycomplexes (CACs) in sera of CHB patients (J.Virol 2018:e00798-18). Recently, we have developed
and validated a novel microplate-based C1q (an essential component of complement system)
capture assay which enables relative quantification of Capsid-specific immune complex in patient
serum. Here, we plan to further evaluate this assay using clinical samples from CHB patients in
Australia, and systematically analyse its statistical relationship with the major clinical parameters
related to stage of disease. This new assay has the potential to reveal the underlying inflammation
that might be missed by conventional biochemical test. It may also be useful for monitoring the
efficacy of current antiviral therapy.
| Short title | EOI - ACH2 pilot ELISA |
|---|---|
| Status | Finished |
| Effective start/end date | 22/11/21 → 28/02/23 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.